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INTRODUCTION
Synovial sarcoma was initially described by Simon [1] in 1865 and was termed as synovial sarcoma in 1938 by Sabrazes et al. [2] due to its resemblance to the developing synovial tissue under the light microscope. However, it has no demonstrable connection or relationship with the synovium. [3] It is a distinctive soft tissue tumor that displays epithelial differentiation. It is more prevalent in adolescent and young adults, 15-40 years of age. Males are affected more than females, with an average male:female ratio of 1.2:1. [4] Classical synovial sarcoma has a biphasic pattern and is composed of sheets of spindle cells and sharply segregated epithelial cells forming gland-like areas in varying proportions. The poorly differentiated synovial sarcoma represents a form of tumor that can occur in either monophasic or biphasic forms and is often diagnostically challenging. The diagnosis of synovial sarcoma has been facilitated by the inclusion of molecular biological techniques in pathology and the recent incorporation of cytogenetics in the oncologic examination.
To date, synovial sarcoma has been found to occur in several unusual locations, including head and neck, skin, blood vessels, abdominal wall, prostate, nerves, pleural cavity, and kidney. The occurrence of poorly differentiated synovial sarcoma in the mediastinum is rare, but recently the occurrence of this tumor is being increasingly recognized. [5] Here we report further a case of a patient with poorly differentiated monophasic synovial sarcoma of the mediastinum who presented clinically with shortness of breath and progressive weight loss.
CASE REPORT
A 30-year-old man presented to the emergency room complaining of shortness of breath that started suddenly and was progressively increasing in severity, with nonproductive cough for one month, and progressive weight loss. His chest examination showed signs of massive pleural effusion. He was an exsmoker and his past medical history was unremarkable. The radiographic studies showed a large heterogenous mass with multiple cystic degenerating areas measuring 10 × 9.5 cm in the anterior mediastinum with massive right-sided pleural effusion. In addition, there were multiple pulmonary and pleural soft tissue deposits, largest measuring 3.4 cm and multiple enlarged right axillary and mediastinal lymph nodes showing a heterogenous enhancement [ Figure 1 ]. The computerized tomography (CT) scan of the abdomen was unremarkable; with no evidence of metastasis. Thoracocentesis was performed to examine pleural effusion, which was hemorrhagic, serous, and exudative with numerous lymphocytes in the background. No malignant cell was seen.
The CT-guided percutaneous needle biopsy was performed, which on gross consisted of five linear fragments, each We resorted to molecular studies for the confirmation of the diagnosis. Fluorescent in situ hybridization (FISH) analysis revealed translocation of chromosome (X; 18) (p11.1; q11.2) [ Figure 5 ], which confirmed the diagnosis of synovial sarcoma. The presence of a large mass in the anterior mediastinum, multiple nodules in the pleura and lung, multiple enlarged mediastinal lymph nodes, with the histologic picture of undifferentiated small cells, the immunohistochemistry and molecular study favoring synovial sarcoma, the final diagnosis of metastatic poorly differentiated monophasic synovial sarcoma was rendered. However, we were not able to identify the primary tumor, even after exhaustive metastatic workup. The patient is alive 6 months after his diagnosis and has received 3 cycles of ifosfamide-based chemotherapy. On repeat CT, there is interval regression of anterior mediastinal mass with necrosis, necrotic pleuropulmonary nodules and mediastinal lymph nodes.
DISCUSSION
The mediastinum is a unique anatomic area containing several structures and pleuripotent cells that allow for the development of a range of tumors. In a study conducted by Burt et al, [5] of the total of 3149 soft tissue sarcomas reviewed in different sites, primary mediastinal sarcoma represented 1.4% of these. The more common primary sarcoma of the mediastinum was malignant peripheral nerve sheath tumor (26%), spindle cell sarcoma (15%), leiomyosarcoma (9%), and liposarcoma (9%). Synovial sarcoma accounted for only 2% of all sarcomas of the mediastinum.
Synovial sarcoma in general is named for their histologic pattern based on the prominence of either epithelioid or spindled cell types. They are divided into four histologic cell types: biphasic, monophasic fibrous, monophasic epithelial, and poorly differentiated. Our case showed predominantly round to epithelioid cells with nuclear features similar to other small round cell tumors. Based on the morphology, our first differential diagnosis was primitive neuroectodermal tumor/ Ewing's sarcoma. Ancillary immunohistochemical and molecular genetic techniques helped to reach the final diagnosis.
It has been recently suggested that vimentin, cytokeratin, and EMA in combination with CD34 negativity are the most useful and sensitive protein biomarkers for the diagnosis of monophasic fibrous synovial sarcoma and poorly differentiated synovial sarcoma. [6] In our case, immunostaining was strongly positive for EMA, vimentin, and Bcl-2 and focally for cytokeratin. The diagnosis of primitive neuroectodermal tumor was ruled out because CD99 was weak and focal. Negativity of lymphoma markers (CD 45, CD20, CD31, CD5, CD30, Tdt, and CD43) and for germ cell tumor (PLAP, alfa-fetoprotein, HCG) led to their exclusion. Negativity of S-100 protein excluded malignant peripheral nerve sheath tumor and negative smooth muscle antigen (SMA) excluded leiomyosarcoma; and p 63 was also negative, which ruled out thymoma. Solitary fibrous tumor was out because of negative CD34. Bcl-2 was positive in our case; however, it is not discriminatory as it is diffusely positive in both solitary fibrous tumor and synovial sarcoma.
Recently with the introduction of molecular and cytogenetic techniques, it has supplemented histology and immunohistochemistry and has led to a better understanding of the biology of synovial sarcoma. [7] The diagnosis in our case was confirmed by molecular detection of tX;18) by fluorescent in situ hybridization. More than 90% of patients have a t(X;18) translocation mutation, which is not associated with other sarcomas. [4] The translocation involves the SYT gene on chromosome 18 (at 18q11) and the SSX1 or SSX2 gene on the X chromosome (at Xp11) [8, 9] These genes appear to be transcription regulators, whose functions occur primarily through proteinprotein interactions. Subtypes of these translocations have been shown to correlate with distinct histologic subtypes. [10] Maha and Shaesta: Synovial sarcoma of mediastinum 
